^
Association details:
| Biomarker: | FGFR2 N549K |
|---|---|
| Cancer: | Gastric Cancer |
| Drug: | Lytgobi (futibatinib) (FGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Abstract 564: Futibatinib (TAS-120) plus chemotherapy demonstrates a synergistic effect across various FGFR-deregulated cancer cell lines and xenograft models
Published date:
05/15/2020
Excerpt:
...gastric FGFR2-amplified SNU-16 and endometrial FGFR2-N549K-mutated AN3CA mouse xenograft models, respectively, by measuring relative tumor volume (RTV). In xenograft models, vs monotherapy, a significant reduction (P<0.01) in RTV occurred with futibatinib plus S-1, paclitaxel (Table), or cisplatin and a numerically greater reduction with futibatinib plus gemcitabine.
Secondary therapy:
cisplatin; gemcitabine; bisphosphonate bound paclitaxel; gimeracil/oteracil/tegafur
DOI:
10.1158/1538-7445.AM2020-564
